La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Embecta a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Embecta..

Embecta (NASDAQ:EMBC) Azioni, Catena delle Opzioni

Embecta

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Embecta Corp

Detroit-based automaker General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) said on Monday that it surpassed selling its 300,000th electric vehicle in the U.S. since 2016 in October. 
What Happened: &#8220;We have more great EVs coming soon, like Cadillac's OPTIQ and ESCALADE IQ, ensuring that when you're ready to make the switch to an all-electric vehicle, you won't have to compromise,&#8221; the company said in a statement. &#8220;GM has spent decades advancing EV technology.&#8221;
GM made a battery electric car as far back as late 90s called the EV1 but the program was eventually terminated in 2001. 
Tesla Inc CEO Elon Musk said in June 2023 that if General Motors had made more EV1s, they would have been the leaders in electric vehicles today. "But they didn't, so there was need for Tesla,&#8221; <a href="https://www.benzinga.com/news/23/06/32910764/general-motors-would-have-been-ev-leaders-if-they-made-more-ev1s-says-tesla-ceo-elon-musk">he said</a>.
According to data from automotive research company Kelley Blue Book, Tesla sold 471,374 EVs in the U.S. through the end of the third quarter, exceeding GM&#8217;s EV sales across nearly 8 years.
Why It Matters: In the third quarter, GM became the second best-seller of EVs in the U.S. after Tesla after selling over 32,000 EVs, with the Chevrolet Equinox EV accounting for a majority of the deliveries.
GM had the longest EV lineup in the U.S. among major players including Tesla in the quarter with eight EV models on sale. 
"We are on track to produce and wholesale approximately 200,000 EVs this year and reach variable profit positive in Q4. Our EV momentum is growing," company CFO&nbsp;Paul A Jacobson&nbsp;<a href="https://www.benzinga.com/markets/equities/24/10/41485013/gm-accelerates-its-ev-ambitions-after-a-strong-q3-in-us-powers-it-past-ford-aims-for-200k-wholes">said </a>during the company&#8217;s third-quarter earnings call last month. 
For the third quarter, GM reported better-than-expected<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462946/general-motors-strong-q3-earnings-impress-analysts-highlights-turnaround-and-ev-pro" target="_blank" rel="noreferrer noopener"> results</a>.
GM's quarterly adjusted earnings per share of $2.96 beat the street view of $2.43. Quarterly sales of $48.757 billion also beat the analyst consensus estimate of $44.585 billion.
The company also raised 2024 adjusted EPS guidance from $9.50 – $10.50 to $10.00 – $10.50.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41708446/tesla-shares-slide-in-pre-market-as-sales-of-elon-musk-led-companys-made-in-china-evs-drop-in-octobe">Tesla Shares Slide In Pre-Market As Sales Of Elon Musk-Led Company&#8217;s Made-In-China EVs Drop In October</a></li>
</ul>
Photo courtesy: GM

News

Tech

TSLA

GM Crosses 300K EV Deliveries In US Since 2016, But It's Still Over 40% Lower Than Tesla's Sales In The First 9 Months Of 2024

Boeing Co.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) 33,000 International Association of Machinists and Aerospace Workers ratified a groundbreaking four-year contract, achieving a 43.65% compounded wage increase and a $12,000 ratification bonus. 
What Happened:&nbsp;This deal, supported by President Joe Biden and Vice President Kamala Harris&#8216; administration and facilitated by Acting U.S. Secretary of Labor Julie Su, ends a nearly two-month strike across Washington, Oregon, and California.
The contract introduces key benefits, including a 38% wage increase over four years, enhanced retirement contributions, and improved health benefits. 
IAM leaders Jon Holden and Brandon Bryant praised the agreement, calling it a major victory for the middle class and a new standard for aerospace industry workers.
Price Action: Boeing&#8217;s stock closed at $155.07 on Monday, marking a modest gain of 0.31% during regular trading hours. In after-hours trading, the stock saw an additional rise, climbing 0.63%. Year to date, however, Boeing&#8217;s stock has faced a significant decline, down 38.41%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734875/palantirs-ai-gamble-pays-off-as-customer-revenue-from-single-customer-jumps-12x-in-under-8-month">Palantir&#8217;s AI Gamble Pays Off As Customer Revenue From Single Customer Jumps 12x In Under 8 Months — Alex Karp Quips: &#8216;We Should Just Go Home&#8217;</a></li>
</ul>
Image via Flickr
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Equities

Management

Markets

Boeing Workers End Seven-Week Strike By Accepting New Contract With Major Pay Increases

Capital Southwest estimates that the proceeds from the offering will be approximately $193.6 million (or approximately $222.7 million if the underwriters exercise their option to purchase additional notes in full), after deducting underwriting discounts and commissions and estimated expenses payable by Capital Southwest. Capital Southwest expects to use the net proceeds from the offering to redeem in full its 4.50% Notes due 2026, to repay a portion of the outstanding indebtedness under its senior secured revolving credit facility with ING Capital LLC, and for general corporate purposes.

CSWC

Capital Southwest Prices $200M 5.125% Convertible Notes Due 2029, Convertible At 12% Premium, Closing Expected November 8

Avista Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVA#NYSE">AVA</a>) today signed a nonbinding memorandum of understanding with North Plains Connector LLC, a wholly owned entity of Grid United,&nbsp;in the development of the North Plains Connector, an approximately 420-mile high-voltage direct-current (HVDC) transmission line to be constructed with endpoints near&nbsp;Bismarck, North Dakota&nbsp;and&nbsp;Colstrip, Montana. The parties will now work to finalize definitive agreements regarding Avista's participation, which is expected to involve a 10% ownership share of the project.
Under the terms of the memorandum of understanding, North Plains Connector LLC will continue to fund the development of North Plains Connector. Avista would invest when the project is operational.

Reported Earlier, Avista Enters North Plains Connector Project With PGE And ALLETE In 3,000 MW East-West Transmission Line

Outlook
The Company is lowering its previously provided EPS guidance for the full year. ADM now expects adjusted earnings per share2 in the range of $4.50 to $5.00 for the full year 2024, based on trends in ADM's performance to date, legislative and regulatory policy uncertainties, and ongoing headwinds from slower market demand and internal operational challenges.

Guidance

Reported Earlier, ADM Lowered Its 2024 Adj. EPS Guidance To $4.50-$5.00 (Prior $5.25-$6.25) Vs. $5.23 Est.

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) announced it will make its open-source Llama artificial intelligence models available to U.S. government agencies working on national security and defense applications, marking a significant expansion of the <a href="https://www.benzinga.com/news/24/11/41734318/mark-zuckerbergs-nuclear-powered-ai-ambitions-at-meta-stung-by-rare-bees">technology&#8217;s authorized use cases</a>.
The social media giant is partnering with major government contractors and technology firms including Amazon.com Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Services, Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), and Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) to implement these AI models across various defense initiatives.
&#8220;As an American company, and one that owes its success in no small part to the entrepreneurial spirit and democratic values the United States upholds, Meta wants to play its part to support the safety, security and economic prosperity of America – and of its closest allies too,&#8221; said Nick Clegg, President of Global Affairs at Meta.
Several contractors have already begun implementing Llama in their operations:
<ul>
<li>Oracle is using the technology to improve aircraft maintenance by helping technicians diagnose problems more quickly</li>
<li>Scale AI is fine-tuning the model for national security missions and identifying potential vulnerabilities</li>
<li>Lockheed Martin has integrated Llama into its AI Factory for code generation and data analysis</li>
<li>Amazon Web Services and Microsoft Azure are hosting the models on secure cloud platforms for sensitive government data</li>
</ul>
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41734875/palantirs-ai-gamble-pays-off-as-customer-revenue-from-single-customer-jumps-12x-in-under-8-month">Palantir&#8217;s AI Gamble Pays Off As Customer Revenue From Single Customer Jumps 12x In Under 8 Months — Alex Karp Quips: &#8216;We Should Just Go Home&#8217;</a>
Why It Matters: Meta emphasized that making Llama available for defense applications aligns with U.S. interests in the global AI race, particularly as nations like China invest heavily in <a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d">developing their own open-source models</a>.
The company noted that large language models can support various aspects of national security, including streamlining logistics, tracking terrorist financing, and strengthening cyber defenses.
Beyond military applications, Meta highlighted broader public sector benefits, with Deloitte implementing Llama-based solutions for government agencies and nonprofits to improve public service delivery in areas such as education and energy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734887/cathie-woods-latest-shake-up-dumps-palantir-and-jack-dorseys-block-along-with-tesla-buys-amazon-">Cathie Wood&#8217;s Latest Shake-up: Dumps Palantir And Jack Dorsey&#8217;s Block Along With Tesla, Buys Amazon And Meta</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Global

AMZN

MSFT

ORCL

PLTR

Meta, Amazon, Microsoft Partner On Defense AI Initiative

PolitiFi tokens themed around Donald Trump and Kamala Harris were getting dumped ahead of the Tuesday presidential elections.
What happened: Maga, the largest Trump-inspired coin, dropped 0.5% over the last 24 hours, while Maga Hat crashed over 16% in this period, <a href="https://www.coingecko.com/en/categories/politifi">according </a>to CoinGecko.
Doland Tremp, parodying the former president's name, also tanked over 6%.&nbsp;
Meanwhile, coins mimicking Vice President Kamala Harris weren't spared either, with Kamala Horris, the largest of all Harris-themed tokens in terms of market cap, slipping 9%.&nbsp;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 11:50 p.m. EDT)</td>
</tr>
<tr>
<td>Maga (TRUMP)</td>
<td>-0.5%</td>
<td>$3.45</td>
</tr>
<tr>
<td>Maga Hat (MAGA)</td>
<td>-16.6%</td>
<td>$0.0001772</td>
</tr>
<tr>
<td>Doland Tremp (TREMP)</td>
<td>-6.4%</td>
<td>$0.2942</td>
</tr>
<tr>
<td>Kamala Horris (KAMA)</td>
<td>-9.6%</td>
<td>$0.0123</td>
</tr>
<tr>
<td>Kumala Herris (MAWA)</td>
<td>-0.6%</td>
<td>$0.003158</td>
</tr>
</tbody>
</table>
</figure>
That said, on a weekly timeframe, KAMA was the clear winner, soaring 58% while most Trump-themed tokens bled heavily.
PolitiFi tokens have been a rage this election year. As the name suggests, these tokens incorporate political themes and campaigns into the cryptocurrency realm.&nbsp;
TRUMP, rooted in Trump's "Make America Great Again" movement, has been the biggest beneficiary, surging an astounding 1171% year-to-date. KAMA, on the other hand, has fallen 62% this year.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734728/polymarket-whale-dumps-3m-bet-on-trump-after-legendary-trader-advises-caution-recommend-ag">Polymarket Whale Dumps $3M Bet On Trump After Legendary Trader Advises Caution: &#8216;Recommend Against Leverage And Reckless Gambling&#8217;</a>
Why It Matters: These moves come as both presidential candidates gear up for the ultimate fight on Tuesday.
Betting platforms like Polymarket and Kalshi are <a href="https://polymarket.com/">leaning </a>toward a Trump win, though the GOP nominee's odds fell drastically over the weekend.
Election polls, however, painted a tighter race, with a new Emerson College election poll <a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">showing the two candidates</a> deadlocked at 49%.&nbsp;
A new Morning Consult poll of likely voters showed <a href="https://www.benzinga.com/general/politics/24/11/41733">Harris maintaining a slender two-point lead</a> over Trump.
Photo Courtesy: Shutterstock.com
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41735471/coinbase-ceo-brian-armstrong-criticizes-regulatory-overreach-nothing-to-capture-in-small-g">Coinbase CEO Brian Armstrong Criticizes Regulatory Overreach: &#8216;Nothing To Capture In Small Government&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Trump, Harris-Inspired Cryptos Crack Ahead Of Election Day—Coin Parodying Vice President Still Up Over 50% This Week

On Monday, Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) unveiled its <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">third-quarter financial results</a>, underscoring its distinctive strategy of maximizing AI models, a move that sets it apart in the AI race.
What Happened: During the company earnings call, Palantir&#8217;s chief revenue and legal officer,&nbsp;Ryan Taylor, shed light on the company&#8217;s unique AI strategy.
He pointed out that while most investments are geared towards enhancing AI models, Palantir&#8217;s approach is to maximize these models within the enterprise context.
Taylor stressed that the capability to effectively leverage these models is what distinguishes the &#8220;AI haves&#8221; from the &#8220;AI have-nots.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41678522/jim-cramer-warns-apple-stock-should-have-never-been-up-that-much-after-q3-earnings-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Warns Apple Stock Should Have &#8216;Never Been Up That Much&#8217; After Q3 Earnings Even As This Analyst Defends iPhone 16 Launch</a>
In essence, Palantir positions itself not as a model creator but as an AI application leader, enabling clients to extract real-world value from AI by leveraging rich, context-driven data and a unique infrastructure — an approach he said will become increasingly valuable in this &#8220;winner-takes-all&#8221; AI economy.
Taylor shared examples of how Palantir's strategy has benefited clients, such as a global insurance firm that reduced underwriting response times from over two weeks to just three hours.
Another example included Associated Materials, which increased its on-time delivery rates from 40% to 90%.
Palantir&#8217;s unique AI approach has also significantly influenced its bottom line, he stated. The company sealed 104 deals over $1 million last quarter, and its U.S. Commercial business continues to gain traction in both expansions and new customer acquisitions.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Palantir&#8217;s third-quarter earnings beat expectations, with total revenue up 30% year-over-year, driven by an&nbsp;&#8216;unrelenting AI demand&#8217;&nbsp;that shows no signs of slowing down.
The company&#8217;s <a href="https://www.benzinga.com/markets/equities/24/11/41734875/palantirs-ai-gamble-pays-off-as-customer-revenue-from-single-customer-jumps-12x-in-under-8-month">unique AI strategy has paid off</a>, with one equipment rental company increasing its annual recurring revenue twelvefold in less than eight months after implementing Palantir's AI platform.
Palantir&#8217;s robust performance has earned it the title of&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41732827/messi-of-ai-wall-street-analyst-gushes-over-robust-earnings-from-palantir">&#8216;The Messi of AI&#8217;</a>&nbsp;from Wedbush analyst Dan Ives.
Despite the skeptics honing in on valuation for the past year, this was a major quarter to prove that PLTR&#8217;s partner ecosystem expansion and AIP bootcamps hit another gear," Ives said following the latest earnings report.
Last month, Palantir also <a href="https://www.benzinga.com/markets/equities/24/10/41141540/palantir-technologies-partners-with-edgescale-ai-to-operationalize-ai-in-manufacturing-and-utili">announced a strategic partnership</a> with Edgescale AI Inc. to launch Live Edge, an innovative integration of Palantir Edge AI and Edgescale AI's distributed infrastructure technology.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41703422/google-delivers-new-ai-features-to-maps-google-earth-waze-apps?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Google Delivers New AI Features To Maps, Google Earth, Waze Apps</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

'AI Haves Vs. Have-Nots': Palantir's Ryan Taylor Outlines Company's Winning Strategy

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Monday.
U.S. stocks settled lower on Monday, with the Dow Jones index falling more than 250 points as investors braced for the high-stakes presidential election.
On the economic data front, U.S. factory orders declined by 0.5% from the previous month to $584.2 billion in September compared to a revised 0.8% fall in August.
Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) shares gained more than 7% on Monday after the company reported better-than-expected third-quarter EPS and revenue.
Shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) have gained around 182% year-to-date, while Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) has lost over half its value this year.
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, communication services, and financials stocks recording the biggest losses on Monday. However, energy and real estate stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 258 points to 41,794.60 on Monday. The S&amp;P 500 fell 0.28% to 5,712.69, while the Nasdaq Composite fell 0.33% to close at 18,179.98 during Monday's session.
Investors are awaiting earnings results from Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) and Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 42.9, the index remained in the &#8220;Fear&#8221; zone on Monday, versus a prior reading of 44.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Pre-Market Outlook

Trading Ideas

INTC

NVDA

YUMC

Dow Tumbles 250 Points As Investors Brace For High-Stakes Presidential Election: Greed Index Enters 'Fear' Zone

Emerson Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/news/earnings/24/08/40222134/emerson-electric-posts-strong-q3-sales-growth-updates-2024-outlook">opening bell on Tuesday, Nov. 5.</a>
Analysts expect the Saint Louis, Missouri-based company to report quarterly earnings at $1.47 per share, up from $1.29 per share in the year-ago period. Emerson Electric projects to report revenue of $4.57 billion for the quarter, compared to $4.09 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Aug. 21, Emerson announced it has made a strategic investment through its corporate venture capital arm Emerson Ventures in Symmera.
Emerson Electric shares gained 1.2% to close at $109.81 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stephens &amp; Co. analyst Tommy Moll downgraded the stock from Overweight to Equal-Weight and cut the price target from $135 to $120 on Oct. 16. This analyst has an accuracy rate of 80%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/590b5cc4290fa700017b6a59/christopher-glynn">Oppenheimer analyst Christopher Glynn</a> maintained an Outperform rating and increased the price target from $120 to $125 on Sept. 26. This analyst has an accuracy rate of 83%.</li>
<li>Morgan Stanley analyst Chris Snyder initiated coverage on the stock with an Underweight rating and a price target of $105 on Sept. 6. This analyst has an accuracy rate of 74%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781de5064ed0001730078/stephen-tusa">JP Morgan analyst Stephen Tusa </a>downgraded the stock from Overweight to Neutral and slashed the price target from $132 to $115 on Aug. 14. This analyst has an accuracy rate of 69%.</li>
<li>RBC Capital analyst Deane Dray maintained an Outperform rating and lowered the price target from $140 to $139 on Aug. 8. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying EMR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05005151/image-19-1024x557.png" alt="" class="wp-image-629370" style="width:638px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05005151/image-19-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05005151/image-19-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05005151/image-19-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05005151/image-19.png 1215w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>

Price Target

Analyst Ratings

Emerson Electric Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) to report quarterly earnings at $1.25 per share on revenue of $21.35 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Archer-Daniels-Midland shares rose 0.8% to $55.75 in after-hours trading.</li>
<li>Analysts expect Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) will post quarterly earnings at $1.41 per share on revenue of $1.9 billion. The company will release earnings before the markets open. Yum! Brands shares fell 0.5% to $132.06 in after-hours trading.</li>
<li>Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) reported in-line earnings for its third quarter on Monday. The company reported quarterly earnings of 24 cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $127.091 million, compared to the analyst consensus estimate of $127.092 million. Lattice Semiconductor said it sees fourth-quarter revenue in a range of $112 million to $122 million, versus the $132.03 million estimate. Lattice Semiconductor shares tumbled 17.7% to $42.70 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is projected to report quarterly earnings at 75 cents per share on revenue of $6.45 billion. Super Micro Computer shares fell 0.3% to $25.96 in the after-hours trading session.</li>
<li>Analysts expect Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) to report quarterly earnings at $4.80 per share on revenue of $8.29 billion before the opening bell. Cummins shares gained 1% to $329.00 in after-hours trading.</li>
</ul>
Check This Out:
<ul>
<li> <a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>
Photo courtesy: Shutterstock

LSCC

SMCI

Archer-Daniels-Midland, Yum! Brands And 3 Stocks To Watch Heading Into Tuesday

<ul>
<li>On the second day of the SK AI Summit 2024, SK Telecom introduced Aster(A&#x2A;), an AI-driven personal assistant designed for global users</li>
<li>Aster is designed as an 'Agentic AI,' which goes beyond answering simple queries by understanding user intentions to set goals and complete tasks</li>
<li>SK Telecom plans to collaborate with global search providers, LLM developers, and third-party applications to enhance Aster's functionalities for North American users</li>
</ul>

Reported Earlier, SK Telecom Reveals 'Aster', A Global AI Personal Agent Tailored For Global Users

David Garofalo, Chairman and CEO of Gold Royalty, commented: "The third quarter of 2024 marked an important inflection point for Gold Royalty. Our outlook continues to grow increasingly positive with the ramp up and construction of several key assets across our portfolio. We achieved record revenues, a stable expense profile, and positive net income through the first nine months of 2024 and have reiterated our full year guidance for expected Total Revenue, Land Agreement Proceeds and Interest&#x2A; of $13 to $14 million in 2024. We continue to be excited about the outlook for 2025 as well, with more cash flowing assets, strong commodity prices, and our stable cost structure expected to translate to growing revenues and cash flows next year."

GROY

Gold Royalty Reaffirms FY24 Guidance, Anticipates Total Revenue, Land Proceeds, And Interest Between $13M - $14M

Gold Royalty Q3 Adj. EPS $0.02 Up From $(0.01) YoY, Sales $2.06M Up From $797K YoY

Will Restate Previously Filed Fiscal Year 2023 Form 10-K and Subsequent Forms 10-Q
Postpones Third Quarter Conference Call
ADM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) ("the Company") today reported preliminary financial results for the quarter ended September 30, 2024.
Preliminary&#x2A; Third Quarter 2024 Highlights
<ul>
<li>Net earnings expected to be reported at $18 million, with adjusted net earnings1 of $530 million
<ul>
<li>See below for impact of non-cash charge against GAAP earnings for the third quarter of $461 million related to our Wilmar equity investment</li>
</ul>
</li>
<li>Earnings per share1 expected to be $0.04, with adjusted earnings per share1, 2 of $1.09, both down versus the prior year period</li>
<li>Trailing four-quarter average return on invested capital (ROIC) of 6.6%, trailing four-quarter average adjusted return on invested capital (ROIC)1 of 8.8%</li>
<li>Restatement of previously filed fiscal year 2023 Form 10-K and subsequent Forms 10-Q not expected to materially impact results on a consolidated basis</li>
</ul>
In regards to cash flows, our year to date cash flows from operating activities are expected to be $2.468 billion, with cash flows from operations before working capital1 of $2.341 billion, as compared to cash flows from operating activities of $1.891 billion and cash flows from operations before working capital1 of $3.804 billion for the corresponding prior-year YTD period.

ADM Preliminary Q3 2024 Results: Expects Adjusted EPS Of $1.09 (Vs. $1.25 Estimate), YTD Operating Cash Flow Expected To Be $2.47B; Postpones Q3 2024 Webcast

Brian Armstrong, CEO of Coinbase, criticized the government&#8217;s overreach and lack of transparency amid the ongoing tussle between the cryptocurrency industry and regulatory bodies.
What Happened: On Monday, Armstrong raised concerns about the &#8220;political capture&#8221; of government agencies, which emboldens them to make decisions on matters beyond their jurisdiction.
&#8220;This is part of the problem with big government &#8211; it tends to get captured politically and start painting outside the bounds of the law,&#8221; Coinbase&#8217;s top executive said. &#8220;If you have small government, there is nothing to capture.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is part of the problem with big government &#8211; it tends to get captured politically and start painting outside the bounds of the law If you have small government, there is nothing to capture. <a href="https://t.co/ceqXP0i1Hy">https://t.co/ceqXP0i1Hy</a>
&mdash; Brian Armstrong (@brian_armstrong) <a href="https://twitter.com/brian_armstrong/status/1853531880865362163?ref_src=twsrc%5Etfw">November 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The critical remark came in response to Coinbase&#8217;s legal head Paul Grewal&#8217;s claims about the Federal Deposit Insurance Corporation (FDIC) instructing banks to halt or refrain from offering cryptocurrency-banking services.
&#8220;So far we&#8217;ve uncovered more than 20 examples of the FDIC telling banks to "pause" or "refrain from providing" or "not proceed" with offering crypto-banking services. The public deserves transparency, not an agency that's working behind a bureaucratic curtain,&#8221; Grewal wrote in an X post.
The FDIC didn&#8217;t immediately return Benzinga&#8217;s request for comment.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734728/polymarket-whale-dumps-3m-bet-on-trump-after-legendary-trader-advises-caution-recommend-ag">Polymarket Whale Dumps $3M Bet On Trump After Legendary Trader Advises Caution: &#8216;Recommend Against Leverage And Reckless Gambling&#8217;</a>
Why It Matters: Armstrong&#8217;s comments come in the wake of Coinbase&#8217;s ongoing legal battle with the SEC and the FDIC. The cryptocurrency behemoth <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39526310/coinbase-sues-sec-and-fdic-over-alleged-attempts-to-stifle-crypto-industry">sued these agencies</a> over attempts to hinder the industry&#8217;s access to the banking sector and failing to comply with Freedom of Information Act requests.
Armstrong has previously <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41602107/coinbase-ceo-brian-armstrong-says-next-sec-chair-should-apologize-for-the-damage-done-to-t">criticized the SEC</a> for its inconsistent positions on matters such as whether digital assets qualify as securities and if the SEC has the authority to regulate cryptocurrency exchanges. He said that the SEC&#8217;s approach has caused confusion and undermined trust in regulatory clarity for digital assets.
Coinbase is the largest cryptocurrency exchange in the U.S., allowing trading for coins such as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), and many more. The platform facilitated trades worth over $2 billion over the last 24 hours, <a href="https://www.coingecko.com/en/exchanges">according </a>to CoinGecko.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s">Elon Musk&#8217;s &#8216;DOGE&#8217; Department Mention Gives Dogecoin Boost To Top Of Daily Gainers: Memecoin Spikes 6%</a></li>
</ul>

$BTC

$ETH

COIN

Coinbase CEO Brian Armstrong Criticizes Regulatory Overreach: 'Nothing To Capture In Small Government'

Macro Economic Events

Econ #s

Economics

Reported Earlier, U.K. BRC Retail Sales Monitor (YoY) For October 0.3% Vs. 1.4% Est.; 1.7% Prior

Reported Earlier, China Caixin Services Purchasing Managers Index For October 52.0 Vs. 50.5 Est.; 50.3 Prior

Reported Earlier, Australia Interest Rate Decision For November Unchanged At 4.35%

Popular podcast host Joe Rogan has endorsed Republican nominee Donald Trump for president. His endorsement came after the latest episode of the Joe Rogan Experience, which featured Elon Musk, was made public.
What Happened: On Monday, while releasing his latest podcast on YouTube and X, formerly Twitter, Rogan announced his support for Trump, saying that the Tesla CEO &#8220;makes the most compelling case&#8221; for the former President.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The great and powerful <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>. If it wasn&#39;t for him we&#39;d be fucked. He makes what I think is the most compelling case for Trump you&#39;ll hear, and I agree with him every step of the way. For the record, yes, that&#39;s an endorsement of Trump. Enjoy the podcast <a href="https://t.co/LdBxZFVsLN">pic.twitter.com/LdBxZFVsLN</a>
&mdash; Joe Rogan (@joerogan) <a href="https://twitter.com/joerogan/status/1853614670764015762?ref_src=twsrc%5Etfw">November 5, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/11/41733346/obamas-former-campaign-manager-alarmed-by-early-voting-numbers-as-harris-trump-fight-close-battle-re?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Obama&#8217;s Former Campaign Manager Alarmed By Early Voting Numbers As Harris-Trump Fight Close Battle: &#8216;Republicans Didn&#8217;t Do What They Did Last Time&#8217;</a>
The podcast featuring Musk delved into multiple subjects, including the mental benefits of <a href="https://www.benzinga.com/general/gaming/24/05/38635599/level-up-with-elon-tesla-ceo-musk-reveals-his-top-video-game-picks-with-great-storylines">video games</a>, with the tech mogul suggesting that gaming skills could be indicative of surgical proficiency.
The iconic duo also discussed diet and cognitive health, dismissing the notion that reducing meat consumption significantly impacts climate change.
Free speech and censorship on social media were also discussed, with Rogan thanking Musk <a href="https://www.benzinga.com/news/23/04/31810229/elon-musk-bought-twitter-1-year-ago-a-look-back-at-whats-happened-since-and-what-could-be-next">for buying Twitter</a> and criticizing the platform&#8217;s decision to de-platform Trump. Musk called the decision &#8220;insane.&#8221;
The conversation also touched on government control, misinformation, government overreach, and the vaccine debate. Musk compared the pharmaceutical industry and the FDA to the tobacco industry.
Musk also accused the Department of Justice of going after his company, SpaceX, for <a href="https://www.benzinga.com/23/08/34060586/elon-musk-calls-out-dojs-double-standards-following-federal-agencys-spacex-lawsuit-over-immigrant-hi">not hiring immigrants</a>, even though it's illegal for them to hire non-permanent residents. &#8220;We're damned if we do, damned if we don't.&#8221;
Why It Matters: The 2024 U.S. presidential election is scheduled for Nov. 5 2024 where Democratic nominee Kamala Harris will face off against Republican candidate Trump.
Harris had a slight lead over Trump in the <a href="https://www.benzinga.com/general/politics/24/11/41733277/harris-vs-trump-vice-president-has-two-point-lead-in-final-election-poll-swing-states-remain-clo">final Morning Consult poll</a> before the 2024 presidential election. However, her odds in prediction markets and betting odds have trailed the former president by a wide margin.
The final Emerson poll predicted a<a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-"> close head-to-head matchup</a>, contradicting the commanding victory for Trump forecasted by prediction markets and sportsbooks.
On the final day before the election, Trump regained his advantage over Harris in online prediction markets. However, data analysts from FiveThirtyEight and Nate Silver suggested <a href="https://www.benzinga.com/general/politics/24/11/41730670/prediction-markets-swing-back-to-trump-but-data-analysts-say-its-too-close-to-call">that the race was too close to call</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41701283/trump-praises-his-beautiful-white-skin-after-criticizing-harris?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Praises His &#8216;Beautiful White Skin&#8217; After Criticizing Harris</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Joe Rogan Endorses Trump As Elon Musk Presents 'Compelling Case' For Ex-President: Here's What The Duo Discussed

Embecta Corporation (EMBC) has provided an update. Embecta Corp. has announced the resignation of Brian Capone, the Chief Accounting Officer, effec...

Embecta Corporation Announces Chief Accounting Officer Resignation

The medtech industry's long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading... The integration of AI in healthcare is continuously transforming the operations and processes of the medical field. Companies engaged in the healthcare industry are leveraging artificial intelligence (AI) to advance patients' care and lower costs propelling the medical technology market.
Amid this backdrop, investors could consider investing in sound medtech stocks Baxter International Inc. (<a href="https://stocknews.com/stock/BAX/">BAX</a>), Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>) which are poised for high-growth.
Technology has revolutionized the healthcare segment with cutting-edge devices and innovations resulting in enhanced outcomes, lower costs, and improved access to care. These innovations led to <a href="https://www.marketsandmarkets.com/blog/HC/The-Global-MedTech-Industry-Outlook-2024#:~:text=The%20global%20MedTech%20sales%20are,to%20outgrow%20the%20US%20market.">FDA approvals of 171 artificial intelligence and machine learning</a> (AI/ML)-enabled medical devices for human use. Also, Generative AI and AI-enabled devices in medtech will remain in focus this year.
The medical technology market revenue is projected to reach $598.90 billion in 2024 worldwide with medical devices market likely to dominate. The medical technology market is <a href="https://www.statista.com/outlook/hmo/medical-technology/worldwide">expected to grow at a CAGR of 5.3%</a>, resulting in a market volume of $775.80 billion by 2029. The US is poised to generate highest revenue of $210 billion by 2024 due to increased investment in R&amp;D.
Further, with AI driving innovation in diagnostics, personalized care, and operational efficiency, the <a href="https://www.medicaldevice-network.com/data-insights/artificial-intelligence-in-medical/?cf-view">artificial intelligence in the medical device industry</a> is flourishing. Medical companies are increasingly adopting AI technologies to enhance their operations and patient care. The market is poised to grow to $97.07 billion by 2028, growing at a <a href="https://blog.marketresearch.com/artificial-intelligence-in-medical-devices-market-set-for-unprecedented-growth">CAGR of 44.4%</a>.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, beginning with the third choice.
Stock #3: Baxter International Inc. (<a href="https://stocknews.com/stock/BAX/">BAX</a>)
BAX develops and provides a portfolio of healthcare products worldwide. The company operates in four segments: Medical Products and Therapies; Healthcare Systems and Technologies; Pharmaceuticals; and Kidney Care.
On August 13, BAX and funds managed by global investment firm Carlyle (<a href="https://stocknews.com/stock/CG/">CG</a>) signed a definitive agreement under which Carlyle will acquire BAX's Kidney Care segment, to be named Vantive, for $3.80 billion.
The transaction marks a key milestone in BAX's ongoing business transformation, allowing heightened strategic clarity, operational efficiency and innovation. It also provides increased flexibility to deploy capital toward opportunities to accelerate Baxter's and Vantive's respective growth objectives
On July 30, BAX launched the Helion Integrated Surgical System in Thailand. With the help of operating room integration and cutting-edge technology, Helion simplifies operating rooms to help healthcare institutions in Thailand boost OR efficiency and keeping surgical teams focused and connected.
BAX's <a href="https://www.investopedia.com/terms/n/netsales.asp">net sales</a> increased 2.8% year-over-year to $3.81 billion for the second quarter that ended June 30, 2024. The company's adjusted operating income grew 6.7% from the year-ago value to $522 million. Adjusted net income attributable to Baxter stockholders and adjusted EPS came in at $345 million and $0.68, indicating growth of 3% year-over-year, respectively.
As per the company guidance, BAX expects sales growth of 4% - 5% and adjusted EPS of $0.77 - $0.79 for the third quarter 2024. Further, for the full fiscal 2024, it expects sales growth of 3% and its adjusted EPS is expected to range between $2.93 and $3.01.
Street expects BAX's revenue and EPS for the third quarter (ending September 2024) to increase 3.6% and 14.1% year-over-year to $3.84 billion and $0.78, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
BAX's stock has increased 6.4% over the past month to close the last trading session at $37.54.
BAX's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has an A grade for Growth and a B grade for Value. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, BAX is ranked #27 out of 135 stocks.
<a href="https://stocknews.com/stock/BAX/">Click here</a> to access additional ratings of BAX for Momentum, Sentiment, Quality, and Stability.
Stock #2: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. The company designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products.
On August 7, ZBH signed a definitive agreement to acquire OrthoGrid Systems, Inc., a privately-held medical technology company focused on AI-driven surgical guidance systems for total hip replacement. The acquisition includes OrthoGrid's AI-powered, fluoroscopy-based surgical assistance platform Hip AI&#xAE;, and its FDA-cleared orthopedic applications and over 40 patents.
The strategic acquisition will expand ZBH's hip portfolio with artificial intelligence-driven surgical guidance system.
On June 12, ZBH and RevelAi Health entered into a multi-year co-marketing agreement to commercialize generative AI-powered engagement solutions to advance value-based orthopedic care and health equity. Under the agreement, ZBH Biomet will commercialize RevelAi Health's patient care-management platform, care team dashboard for providers, and any future products or services.
ZBH's revenue and EBITDA have grown at respective CAGRs of 0.7% and 3.3% over the past three years. The company's EBIT has increased 6.3% over the same timeframe, while its net income and EPS have improved at CAGRs of 2.9% and 3%, respectively.
During the second quarter that ended on June 30, 2024, ZBH's net sales increased 3.9% year-over-year to $1.94 billion, and its adjusted gross profit increased 3.3% year-over-year to $1.39 billion. The company's adjusted operating profit grew 7.4% from the year-ago value to $552.60 million.
In addition, net earnings of ZBH and EPS came in at $242.80 million and $1.18, reflecting increases of 15.8% and 18% from the prior year's quarter, respectively.
As per the company guidance for the full year 2024, ZBH expects revenue change of 4.0% - 5.0% and its adjusted EPS is expected between $8 and $8.15.
Analysts expect ZBH's revenue for the third quarter (ending September 2024) to grow 4.7% year-over-year to $1.84 billion and its EPS for the same period is expected to increase 9.3% year-over-year to $1.80. Furthermore, the company surpassed the consensus EPS and revenue estimates in each of the trailing four quarters.
ZBH's shares have gained 4.7% over the past month and marginally over the past year to close the last trading session at $115.05.
ZBH's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value, Growth, and Quality. Within the Medical – Devices &amp; Equipment industry, ZBH is ranked #24 out of 135 stocks.
In addition to the POWR Ratings we've stated above, we also have ZBH ratings for Stability, Momentum, and Sentiment. Get all ZBH ratings <a href="https://stocknews.com/stock/ZBH/">here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a medical device company which focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. The company's portfolio include pen needles, syringes, and safety injection devices, and digital applications to assist people with managing patient's diabetes.
On August 9, EMBC's Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of its common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024.
EMBC pays an annual dividend of $0.60, which translates to a yield of 4.29% at the current share price. Its four-year average dividend yield is 2.33%.
EMBC reported revenues of $272.50 million for the third quarter that ended June 30, 2024, and its adjusted gross profit grew marginally from the year-ago value to $190.30 million. The company's adjusted operating income of $83.30 million indicates a growth of 4.4% from the prior year's quarter.
Furthermore, the company's adjusted net income came in at $43 million and $0.74 per share, up 8% and 7.2% year-over-year, respectively.
As per the company's fiscal year 2024 outlook, EMBC expects its revenues between $1.11 billion and $1.12 billion. The company also revised its adjusted EPS to range from $2.30 to $2.35, compared to the previous guidance of $2.20 - $2.30.
Street expects EMBC's revenue for the fiscal year 2024 (ending September 2025) to increase marginally year-over-year to $1.12 billion and its EPS for the same year is expected to be $2.26. Also, the company has topped the consensus revenue and EPS estimate in all four trailing quarters, which is remarkable.
Shares of EMBC have surged 7.8% over the past three months to close the last trading session at $14.
EMBC's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
EMBC has an A grade for Value and Quality. It also has a B for Growth. The stock has topped among the 135 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have EMBC ratings for Sentiment, Momentum, and Stability. Get all EMBC ratings <a href="https://stocknews.com/stock/EMBC/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZBH shares were trading at $115.26 per share on Monday afternoon, up $0.21 (+0.18%). Year-to-date, ZBH has declined -4.90%, versus a 18.55% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zbh-bax-embc-cg-3-high-growth-medtech-stocks-to-buy/>3 High-Growth MedTech Stocks to Buy</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Growth MedTech Stocks to Buy

Embecta gets FDA clearance for type 2 diabetes patch pump

Morgan Stanley analyst Kallum Titchmarsh maintained a Sell rating on Embecta Corporation (EMBC – Research Report) yesterday and set a price target ...

Recommendation to Sell: Anticipated Costs and Competition Challenge Embecta's New Pump Program

In a report released yesterday, Marie Thibault from BTIG reiterated a Hold rating on Embecta Corporation (EMBC – Research Report). The company's sh...

BTIG Reaffirms Their Hold Rating on Embecta Corporation (EMBC)

Embecta Corp.: Navigating Through A Changing Landscape

The medical industry is on the fence of explosive growth, fueled by technological advancements. In this evolving landscape, investors could consider investing in promising medical device stocks like Hologic, Inc. (HOLX), Avanos Medical (AVNS), and Embecta Corp. (EMBC) with solid growth prospects. Learn more… Thanks to cutting-edge technology, medical stocks are effectively reshaping the healthcare sector. The industry is experiencing significant growth, driven by increasing demand for advanced healthcare solutions, particularly in diagnostics, surgeries, and patient monitoring.
Given this backdrop, investors looking for growth opportunities could take a look at these three fundamentally robust medical device stocks: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>), Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>). These companies are shaping healthcare delivery's future and benefitting from technological advancements.
The medical devices industry is poised for steady growth as its market size is anticipated to reach <a href="https://www.mordorintelligence.com/industry-reports/global-medical-device-technologies-market-industry?network=g&amp;source_campaign=&amp;utm_source=google&amp;utm_medium=cpc&amp;matchtype=b&amp;device=c&amp;gad_source=1&amp;gclid=Cj0KCQjwpP63BhDYARIsAOQkATb9SdZ7QZMMYB0trPXq_zr3V73FHtcX5g9Z7xWnrv4R67MwdKzHOV0aApKdEALw_wcB">$893.07 billion by 2029</a>, exhibiting a CAGR of 7%. Moreover, by 2030, the global annual medical device sales are forecasted to <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html#:~:text=The%20medical%20device%20industry%20is,US%24800%20billion%20by%202030%20.">hit $800 billion</a>.
Moreover, innovations like AI-powered diagnostic tools, wearable health devices, and robotic surgery systems are revolutionizing patient care. The FDA has already authorized <a href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#:~:text=the%20FDA%20has%20authorized%20950%20AI/ML%2Denabled%20medical%20devices.">950 AI/ML-enabled medical devices</a>, which promise faster diagnoses, more precise treatments, and improved patient outcomes.
Considering these favorable trends, let's look at the fundamentals of the above-mentioned <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> picks in detail:
Stock #3: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>)
HOLX is a medical technology company focused on improving women's health and well-being through early detection and treatment. It is a developer, manufacturer, and supplier of worldwide diagnostics, medical imaging systems, and surgical products. The company operates through four segments: Diagnostics; Breast Health; GYN Surgical; and Skeletal Health.
On July 25, HOLX acquired Endomagnetics Ltd., a privately held UK-based developer of breast cancer surgery technologies, for $310 million. This acquisition enhances access to Endomag's innovative technologies and diversifies HOLX's expanding interventional breast health portfolio.
In the fiscal third quarter that ended on June 29, 2024, HOLX's total revenue increased 2.7% year-over-year to $1.01 billion with a non-GAAP gross margin of 61.1% (up 30 bps year-over-year). The company reported income from operations of $244 million, indicating a significant growth from the prior year quarter.
In addition, its adjusted EBITDA increased 8.5% year-over-year to $338.50 million. HOLX's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $250.70 million, up 8.4% year-over-year, while its non-GAAP EPS grew 14% from the year-ago value to $1.06.
For the fourth quarter of the fiscal year 2024, the company's revenue is projected to be between $970 million and $985 million, with non-GAAP EPS anticipated to fall between $0.97 and $1.04.
The consensus revenue estimate of $977.49 million for the fiscal fourth quarter (ended September 2024) represents a 3.4% increase year-over-year. The consensus EPS estimate of $1.01 for the same quarter indicates a 13.9% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past three and five years, HOLX's total assets grew at CAGRs of 1.2% and 6.4%, respectively. Also, the company's normalized net income and operation income (EBIT) have increased at a CAGR of 16.8% and 10.9%, respectively, over the past five years.
Shares of HOLX have gained 14.3% over the past year to close the last trading session at $79.22.
HOLX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
HOLX has a B grade for Growth and Quality. It is ranked #14 out of 134 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/HOLX/">Click here</a> to see the additional ratings for HOLX (Value, Momentum, Stability, and Sentiment).
 Stock #2: Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>)
AVNS is a medical device company that focuses on delivering medical device solutions. The company conducts its business in one segment, which provides its medical device products to healthcare providers and patients globally with manufacturing facilities.
AVNS' net sales for the second quarter (ended June 30, 2024) increased marginally year-over-year to $171.70 million. Its non-GAAP operating profit from continuing operations grew 18.5% from the prior year's quarter to $21.80 million. The company's net income stood at $1.80 million compared to the prior-year quarter's loss of $68.10 million, while its EPS came in at $0.04 versus a loss of $1.46 per share last year.
In addition, AVNS' adjusted EBITDA from continuing operations rose 17% from the year-ago value to $26.80 million. Its free cash flow came in at $21.90 million compared to a year-ago net loss of $6.6 million.
As per the fiscal year 2024 outlook, AVNS forecasts revenue from continuing operations to range between $685 million and $705 million. The company also expects adjusted EPS from continuing operations between $1.30 and $1.45 and adjusted gross margins from continuing operations to fall in the range of 59.5%-60.5%.
Street expects AVNS' revenue for the fiscal third quarter (ended September 2024) to increase 2.4% year-over-year to $175.33 million. Its EPS for the same period is expected to register a 17.8% growth from the prior year, settling at $0.35. In addition, it surpassed the consensus revenue in each of the trailing four quarters, which is promising.
Moreover, AVNS' EBITDA and net income have grown at CAGRs of 32.7% and 47.5%, respectively, over the past three years. In addition, its EPS increased at 60.6% CAGR over the same time frame.
Over the past three months, the stock has surged 18.5%, closing the last trading session at $23.02.
It's no surprise that AVNS has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Growth and a B for Value. Out of 134 stocks in the same industry, AVNS is ranked #12.
Beyond what is stated above, we've also rated AVNS for Momentum, Stability, Sentiment, and Quality. Get all AVNS ratings <a href="https://stocknews.com/stock/AVNS/">here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a global diabetes care company focusing on providing various solutions to enhance the health and well-being of people with diabetes. It has a portfolio of products that include pen needles, syringes, safety injection devices, and digital applications to assist people with managing patient's diabetes. 
On September 3, EMBC received clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system, required for adults who require insulin, both type 1 (T1D) and type 2 (T2D) diabetes, to be managed. This clearance aligns with the company's vision and focuses on developing a patch pump, addressing obstacles to adopting pump therapy for people who use insulin daily to manage their diabetes. 
For the third quarter of 2024, which ended on June 30, EMBC's revenue stood at $272.50 million. Its adjusted operating income grew 4.4% from the year-ago value to $83.30 million. Its adjusted net income for the quarter amounted to $43 million or $0.74 per share, representing an increase of 8% and 7.2%, respectively, from the same period last year. Also, the company reported an adjusted EBITDA of $99.20 million, indicating a 15.5% growth from the prior year's quarter.
The company has updated its fiscal year 2024 financial guidance, increasing its adjusted gross margin projection to a range of 65.25% to 65.50%, up from the previous estimate of 64.5% to 65%. Additionally, it adjusted its non-GAAP EPS guidance to a new range of $2.30 to $2.35, slightly higher than the prior forecast of $2.20 to $2.30.
Moreover, its adjusted EBITDA margin is expected to range between 31.25%-31.50%, an increase from the previous estimate of 31%-31.5%. Meanwhile, EMBC projects its revenue to fall in the range of $1.11 billion to $1.12 billion.
Analysts expect EMBC's revenue and EPS for the current year (ending September 2024) to be $1.11 billion and $2.39, respectively. For the fiscal year 2025, its revenue is expected to grow marginally from the prior year to $1.12 billion, and its EPS is projected to come in at $2.27.
Over the past year, EMBC's net income has increased at a CAGR of 47.7%, while its EPS grew at 45.3% CAGR.
EMBC shares have surged 10.1% over the past three months to close the last trading session at $13.29.
EMBC's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and Quality and a B for Growth. Within the Medical - Devices &amp; Equipment industry, it is ranked #3. <a href="https://stocknews.com/stock/EMBC/">Click here</a> to see EMBC's ratings for Momentum, Stability, and Sentiment.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HOLX shares were trading at $79.88 per share on Friday morning, up $0.66 (+0.83%). Year-to-date, HOLX has gained 11.80%, versus a 20.77% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/holx-avns-embc-3-medical-device-stocks-with-strong-growth-prospects/>3 Medical Device Stocks With Strong Growth Prospects</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Device Stocks With Strong Growth Prospects

AVNS

EMBC

HOLX

PODD

TNDM

Dividends

Press Releases

embecta Announces Quarterly Cash Dividend

Embecta Corp. Reports Second Quarter Fiscal 2024 Financial Results

Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

embecta-sponsored Abstracts Presented at American Diabetes Association's 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir

Comments

Embecta

Embecta (EMBC) Opzioni

Embecta (NASDAQ:EMBC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO